Treats acne vulgaris. ANDA 205033, held by Padagis Israel. Adapalene; Benzoyl Peroxide.
As of Nov 21, 2026, ANDA 205033 (Adapalene and Benzoyl Peroxide), held by Padagis Israel, was first approved by FDA on Jan 23, 2018, with 0 approved supplements and 0 published complete response letters.
Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 23, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Adapalene and Benzoyl Peroxide0.1%;2.5% · gel;topical | Adapalene; Benzoyl Peroxide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters